APA (7th ed.) Citation

Liu, J., Xu, M., Zhang, X., Zhang, Z., Zhong, T., Yu, H., . . . Li, L. (2024, July). CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia. Heliyon.

Chicago Style (17th ed.) Citation

Liu, Jie, et al. "CD19 Chimeric Antigen Receptor-T Cells as Bridging Therapy to Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Patients with Refractory/relapsed B-cell Acute Lymphoblastic Leukemia." Heliyon Jul. 2024.

MLA (9th ed.) Citation

Liu, Jie, et al. "CD19 Chimeric Antigen Receptor-T Cells as Bridging Therapy to Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Patients with Refractory/relapsed B-cell Acute Lymphoblastic Leukemia." Heliyon, Jul. 2024.